News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiola Penetrates European Market with Its Muscular CounterPulsation (MCP)-based m.pulse(R) system


9/2/2009 10:55:27 AM

WINTERTHUR, Switzerland--(BUSINESS WIRE)--Cardiola AG announced today that it has placed its patented m.pulse® system in 10 hospitals located in Germany and Switzerland, on the heels of the system’s CE-Mark approval. MCP was previously only available in a clinical setting. Now, m.pulse® is the world’s first and only device enabling CAD patients to receive MCP therapy at home.

Read at BioSpace.com


comments powered by Disqus
Cardiola
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES